Neutralization of DHG, a new depolymerized holothurian glycosaminoglycan, by protamine sulfate and platelet factor 4

Pathophysiology of Haemostasis and Thrombosis

Volumn 27, Issue 4, 1997, Pages 174-183

  Sasaki, Eiji ^a   Minamiguchi, Kazuhisa ^a   Kitazato, Keiko T ^a   Nagase, Hideki ^a   Kitazato, Kenji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

DHG; Heparin; Low molecular weight; Neutralization; Platelet factor 4; Protamine sulfate; Unfractionated

Indexed keywords

HEPARIN; HOLOTHURIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TIME; DRUG ANTAGONISM; DRUG EFFECT; FIBRINOLYSIS; HEMOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLEEDING TIME; DRUG INTERACTIONS; GLYCOSAMINOGLYCANS; HEPARIN ANTAGONISTS; HEPARIN COFACTOR II; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET FACTOR 4; PROTAMINES; RATS; RATS, WISTAR; THROMBIN TIME;

EID: 0031437427     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217453     Document Type: Article

References (35)

1. Kelton JG, Hirsh J: Bleeding associated with antithrombotic therapy. Semin Hematol 1984;17:375-379.
2. Hirsh J: Heparin induced bleeding. Nouv Rev Fr Hematol 1984;26: 261-266.
3. Jaques LB, Kavanagh LW: Protamine neutralization factors for heparin. Can J Pharm Sci 1977; 12: 44-47.
4. Kuitunen AH, Salmenpera MT, Heinonen J, Rasi VP, Myllyla G: Heparin in patients undergoing coronary artery bypass surgery. J Car-diothorac Vase Anesth 1991;5:221-226.
5. Niewiarowski S, Thomas DP: Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature 1969,222: 1269-1270.
6. Levine SP, Wohl H: Human platelet factor 4: Purification and characterization by affinity chromatography. JBiolChcm 1976;251:324-328.
7. Loscalso J, Melnick B, Handin RI: The interaction of platelet factor 4 and glycosaminoglycans. Arch Bio-chem Biophys 1985,240:446-455.
8. Dawes J, Pumphrey CW, Mclaren KM, Prowsc CV, Pepper DS: The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982;27: 65-76.
9. Rao AK, Niewiarowski S, James P, Holt JC, Harris M, Elfcnbcin B, Bastl C: Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 1983;61: 1208-1214.
10. Walz DA, Hung GL: In vivo studies on the binding of heparin and its fractions with platelet factor 4. Semin Thromb Hemost 1985:11:40-47.
11. Bush C, Owen WG: Identificaiion in vitro of an endothelial cell surface cofactor for antithrombin III. J Clin Invest 1982;69:726-729.
12. Marcum JA, Mckenney JB. Rosenberg RD: Acceleration of thrembin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984:74:341-350.
13. Rucinski B, Knight LC, Niewiarowski S: Clearance of human platelet factor 4 by liver and kidney: Its alteration by heparin. Am J Physiol 1986;25 :H800-H807.
14. Handin RI, Cohen HJ: Purification and binding properties of human platelet factor four. J Biol Chem 1976;251:4273-4282.
15. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U: Anticoagulant activities of heparin of.gosac-charides and their neutralization by platelet factor 4. Biochcm J 1984; 218:725-732.
16. Nagase H, Enjyoji K, Shima M, Ki-tazato K, Yoshioka A, Saito H, Kato H: Effect of depolymerized holothu-rian glycosaminoglycan (DHG) on the activation of factor VIII and factor V by thrombin. J Biochem 1996; 119:63-69.
17. Nagase H, Enjyoji K, Minamiguchi K, Kitazato TK. Kitazato K, Saito H, Kato H: Depolymerized holothu-rian glycosaminoglycan with novel anticoagulant actions: Antithrombin III-and heparin cofactor 11-independent inhibition of factor X activation by factor IXa-factor Villa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 1995;85:1527-1534.
18. Nagase H, Kitazato TK, Sasaki E, Hattori M, Kitazato K, Saito H: Antithrombin Ill-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice. Thromb Haemost 1997;77:399-402.
19. Kitazato K, Kitazato TK, Nagase H, Minamiguchi K: DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats. Thromb Res 1996; 84:111-120.
20. Minamiguchi K, Nagase H, Kitazato TK, Kitazato K: Interaction of a new depolymerized holothurian glycosaminoglycan with proteins in human plasma. Thromb Res 1996;83: 253-264.
21. Yoshlda K, Minami Y, Nemoto H, Numata K, Yamanaka E: Structure of DHG, a depolymerized glycosaminoglycan from sea cucumber, Stichopus japonicus. Tetrahedron Lett 1992;33:4959-4962.
22. Dejana E, Villa S, De Gaetano G: Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemost 1982;48: 108-111.
23. Van Ryn-Mc Kcnna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR: Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost 1990;63:271-274.
24. Cobel-Geard RJ, Hassouna HI: Interaction of protamine sulfate with thrombin. Am J Hematol 1983:14: 227-233.
25. Inagaki M. Goto K, Katayama H, Benson KT, Goto H, Arakawa K: Activated partial thromboplastin time-protamine dose relation in the presence and absence of heparin. J Cardiothorac Anesth 1989;3:734-736.
26. Diness V, Ostergaard PB: Neutralization of a low molecular weight heparin (LNH-1) and conventional heparin by protamine sulfate in rats. Thromb Hacmost 1986;56:318-322.
27. Lacoviello L, D’Adamo MC, Pawlak K, Polishchuck R, Wollny T, Bucz-ko W, Donati MB: Antithrombotic activity of dermatan sulphates, hep-arms and their combination in an animal model of arterial thrombosis. Thromb Hacmost 1996,76: 1102-1107.
28. Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR: The haemorrhagic and antithrombotic effects of dermatan sulfate. Br J Haematol 1986:64:309-317.
29. Cook JJ, Niewiarowski S, Yan Z, Schaffer L, Lu W, Stewart GJ. Mos-ser DM, Myers JA, Maione TE: Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Circulation 1992;85:1102-1109.
30. Bernabei A, Gikakis N. Maione TE. Kowalska MA, Yan Z, Niewiarowski S, Edmunds LH Jr: Reversal of heparin anticoagulation by recombinant platelet factor 4 and prolamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardio-vascSurg 1995;109:765-771.
31. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnern EM: Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995;91:2188-2194.
32. Kaplan KE, Owen J: Radioimmunoassay of platelet factor 4. Methods Enzymol 1982;84:83-92.
33. Kaplan KL, Owen J: Plasma levels of ß-thromboglobulin and platelet factor 4 as indicates of platelet activation in vivo. Blood 1981;57:199-202.
34. Tsukasato T. Maruyama I, Ohkatsu Y: Heparin infusion test: Releasable PF4 and endothelial antithrombo-genic activity. Blood Vessels 1989; 20:96-99.
35. O’brien JR. Etherington MD, Pash-ley M: Intra-platelet factor 4 (IPPF4) and the hcparin-mobilisa-ble pool of PF4 in health and atherosclerosis. Thromb Haemost 1984; 51:354-357.